Nomination withdrawn — not under FDA review
Where to Buy Ipamorelin
Ipamorelin is grouped constantly with compounds whose status is genuinely open, and its own is not open in that way.
Ipamorelin gets no seller list on this board. The dated status note on the board records where it stands, and what it records is a settled absence rather than a process still running.
That is worth separating from the other empty boards here. Several of them mark questions that remain live. This one does not, and borrowing their phrasing would quietly turn a plain absence into an implied wait.
No path to a future table is described, because none can be described honestly. The record and its date are what the board offers, and they are enough for a reader to judge a seller's claims against.
Regulatory status, as of September 2026
The nomination that would have put ipamorelin on the Section 503A bulk drug substances list was withdrawn. Ipamorelin was not among the peptides the FDA Pharmacy Compounding Advisory Committee reviewed on July 23-24, 2026. So there is no vote to report, no recommendation for or against, and no rulemaking waiting on anything. Readers who have seen headlines about that meeting should know that ipamorelin was not part of it. There is no timeline to offer, and none is invented here. This page records the absence of a status rather than implying a favorable one.
With the nomination withdrawn there is no pending decision to track, so no route to a board can be described. Should something enter the public record that changes where ipamorelin stands, it gets dated here, with a plain statement of what it does and does not mean.
What this board covers
Nothing is ranked here, and nothing is promised in place of a ranking. A compound earns a scored board on this site once a licensed US telehealth seller dispenses it under facts a reader can verify independently. Ipamorelin is not in that position, and the dated note states the situation without dressing it up.
What Ipamorelin is
Ipamorelin is a synthetic peptide that acts on the growth-hormone secretagogue receptor, the same receptor the hormone ghrelin binds. It usually comes up alongside growth-hormone-releasing hormone analogues. It holds no FDA approval in the United States. What follows is a status record and nothing else.
What the evidence shows
Ipamorelin has a defined receptor target and short-term human pharmacology behind it, which places it in the limited evidence tier rather than the empty one. What does not exist is the controlled long-term human data that the anti-aging and recovery claims attached to it would require. Most marketing for this compound lives in the gap between those two things. No study count is attached to this summary.
What to watch for
- Ipamorelin sold as a blended vial with a growth-hormone-releasing hormone analogue. A blend obscures how much of each compound is present and makes seller-to-seller comparison impossible.
- Short-term hormone measurements marketed as long-term results. A blood marker moving is not the outcome buyers are being sold, and the two are used interchangeably in almost every listing.
- Vials described as pharmaceutical grade or lab tested with nothing to check behind the phrase. A certificate a buyer cannot trace to an independent lab is a design element.
- Storefronts implying ipamorelin is somewhere in a regulatory process. The dated status note on this board says otherwise, and that gap is a useful signal about the seller repeating it.
Frequently asked questions
Why is this board empty when other compounds here are called pending?
Empty covers two different situations on this site. Some boards mark an open question. Ipamorelin has none attached to it, and the dated status note keeps that difference visible rather than letting one read as the other.
Is ipamorelin under review?
Nothing on the public record supports saying so, and no guess is offered in its place. The dated status note states the position, including what is not there.
Clinics offer ipamorelin now. Why are none compared?
Their dispensing terms are rarely verifiable from outside the storefront, and a comparison needs facts a reader can check. Without those, a ranked list would only reflect who advertises hardest.
Does an empty board mean ipamorelin is unsafe?
No. The board describes what can be lawfully dispensed and independently checked. That is a different question from safety, and this site does not blur them.
Is ipamorelin the same as CJC-1295?
No. They act through different receptors and are sold together often enough that the names travel as a pair. The comparison article covering both explains what separates them.